CG Oncology, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
CG Oncology, Inc. (CGON) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 8.21 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- CG Oncology, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 7.59M shares, a 14.86% increase year-over-year.
- CG Oncology, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 6.61M shares, a 10.15% increase year-over-year.
- CG Oncology, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 6.00M shares, a 73.89% increase year-over-year.
- CG Oncology, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 3.45M shares.
- CG Oncology, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 7.96M shares, a 21.05% increase from fiscal 2024.
- CG Oncology, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 6.57M shares, a 85.04% decline from fiscal 2023.
- CG Oncology, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 43.95M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 8.21M shares 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | 7.59M shares 10-Q · filed 2026-05-08 | |||
| 2025-12-31 | 7.96M shares 10-K · filed 2026-02-27 | |||
| 2025-09-30 | 7.93M shares 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | 8.96M shares 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | 6.61M shares 10-Q · filed 2026-05-08 | |||
| 2024-12-31 | 6.57M shares 10-K · filed 2026-02-27 | |||
| 2024-09-30 | 5.20M shares 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | 6.04M shares 10-Q · filed 2025-08-08 | |||
| 2024-03-31 | 6.00M shares 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | 43.95M shares 10-K · filed 2026-02-27 | |||
| 2023-09-30 | 4.69M shares 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | 4.48M shares 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | 3.45M shares 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |